High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Bone Marrow Transplantation

Volumn 34, Issue 2, 2004, Pages 161-167

  Kumar, S ^a   Lacy, M Q ^a   Dispenzieri, A ^a   Rajkumar, S V ^a   Fonseca, R ^a   Geyer, S ^a   Allmer, S ^a   Witzig, T E ^a   Lust, J A ^a   Greipp, P R ^a   Kyle, R A ^a   Litzow, M R ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autologous transplantation; Multiple myeloma; Refractory

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; M PROTEIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER SURVIVAL; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIARRHEA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 4043107738     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704545     Document Type: Article

References (40)

1. Bataille R, Harousseau JL. Multiple myeloma. New Engl J Med 1997; 336: 1657-1664.
2. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
3. Kyle RA. Long-term survival in multiple myeloma. New Engl J Med 1983; 308: 314-316.
4. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382-389.
5. Kyle R, Gertz M, Witzig T et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. [see comments.]. N Engl J Med 1996; 335: 91-97.
8. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
9. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
10. Attal M, Harousseau J, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective Randomized Study of the "Intergroupe Francophone du Myelome" (IFM 94) [abstract]. Blood 2002; 100 Abstract # 7.
11. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
12. Stewart FM. Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma. Leukemia 1993; 7: 1091-1094.
13. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267-1272.
14. Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118-121.
15. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
16. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
17. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
18. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
20. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
21. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
22. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
23. Blade J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
24. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245-254.
25. Powles R, Sirohi B, Kulkarni S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'? Bone Marrow Transplant 2002; 30: 479-484.
26. Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
27. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment* Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
28. Alexanian R, Weber D, Delasalle K et al. Value of intensive therapy supported by autologous stem cells (IT+ASCT) for primary resistant multiple myeloma. Blood 2002; 100 abstract: #672.
29. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
30. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843-847.
31. Dimopoulos MA, Hester J, Huh Y et al. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730-734.
32. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860-1866.
33. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
34. Schenkein DP, Koc Y, Alcindor T et al. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor. Biol Blood Marrow Transplant 2000; 6: 448-455.
35. Rajkumar SV, Fonseca R, Lacy MQ et al. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 1999; 23: 1261-1266.
36. Gertz MA, Witzig TE, Pineda AA et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337-342.
37. Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979-983.
38. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on autologous transplantation in multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 132-139.
39. Shimoni A, Smith TL, Aleman A et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821-828.
40. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.